← Leaderboards
Laszlo Farkas
Virginia Commonwealth University
$3,459,308
Attributed
$3,686,535
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $682.6K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,686,535 · 3
By mechanism
R01$3,086,169 · 1
R21$454,454 · 1
R03$145,912 · 1
Top collaborators
- Robert J Freishtat2 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Michael A Fox$7,040,551
- Mario Acunzo$403,089
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungPulmonary Artery StructureCellsBlood VesselsIn VitroPulmonary Arterial HypertensionMortalityHuman DiseasePublic HealthIn VivoMissionEndothelial CellsMorbidity - Disease RatePathogenesisGenesAngiogenesisCellular BiologyPulmonary HypertensionUnited States National Institutes Of HealthVascular RemodelingBasePathway InteractionsCell PhysiologyApoptosis
Grant awards (9)
Regulation and Function of RAB7 in the pulmonary endothelium$625,836
R01 · FY2025 · HL · contact PI
Endothelial Toll-like Receptor 3 in the pathogenesis and therapy of Pulmonary Arterial Hypertension$594,409
R01 · FY2022 · HL · contact PI
Endothelial Toll-like Receptor 3 in the pathogenesis and therapy of Pulmonary Arterial Hypertension$593,180
R01 · FY2021 · HL · contact PI
Endothelial Toll-like Receptor 3 in the pathogenesis and therapy of Pulmonary Arterial Hypertension$590,163
R01 · FY2020 · HL · contact PI
Endothelial Toll-like Receptor 3 in the pathogenesis and therapy of Pulmonary Arterial Hypertension$682,581
R01 · FY2019 · HL · contact PI
Central role of endothelial stem cells in pulmonary arterial hypertension$202,763
R21 · FY2017 · HL · contact PI
Central role of endothelial stem cells in pulmonary arterial hypertension$251,691
R21 · FY2016 · HL · contact PI
Precursor cells in human pulmonary hypertension$71,162
R03 · FY2013 · HL · contact PI
Precursor cells in human pulmonary hypertension$74,750
R03 · FY2012 · HL · contact PI